知识产权

订阅

MedSci主页 / 所有栏目 / 知识产权

如何看懂—专利文献号

2015-03-18 MedSci MedSci原创

专利文献号
关注

（一）专利文献号专利文献是指国家知识产权局按照法定程序公布的专利申请文件和公告的授权专利文件。专利文献种类是指国家知识产权局按照相关法律法规对发明、实用新型、外观设计专利申请在法定程序中予以公布或公告，由此产生的各种专利文献。专利文献号是指国家知识产权局按照法定程序，在专利申请公布和专利授权公告时给予的专利文献标识号码。特点一件专利申请形成的专利文献至始至终只能获得一个专利文献号；例如：发明专利申

（一）专利文献号

专利文献


是指国家知识产权局按照法定程序公布的专利申请文件和公告的授权专利文件。

专利文献种类

是指国家知识产权局按照相关法律法规对发明、实用新型、外观设计专利申请在法定程序中予以公布或公告，由此产生的各种专利文献。

专利文献号

是指国家知识产权局按照法定程序，在专利申请公布和专利授权公告时给予的专利文献标识号码。

特点

一件专利申请形成的专利文献至始至终只能获得一个专利文献号；
例如：发明专利申请公布号与发明专利授权公告号采用同样的专利文献号，其种类区别由相应的专利文献种类标识代码确定。

专利文献号的组成

专利文献号用9位阿拉伯数字表示，包括申请种类号和公布或公告顺序的流水号两部分。
申请种类号（第1位）+文献流水号（第2-9位）

申请种类号用1位阿拉伯数字表示。
1表示发明专利申请；2表示实用新型专利申请；3表示外观设计专利申请。

（二）专利文献种类标识代码

专利文献种类标识代码

是指国家知识产权局为标识不同种类的专利文献而规定使用的字母代码，或者字母与数字的组合代码。

专利文献种类标识代码的组成

以一个大写英文字母，或一个大写英文字母与一位阿拉伯数字的组合表示。
大写英文字母表示：相应专利文献的公布或公告；

阿拉伯数字：用来区别公布或公告阶段中不同的专利文献种类。

专利文献种类标识代码中字母的含义

A  表示发明专利申请公布
B  表示发明专利授权公告
C  表示发明专利权部分无效宣告的公告
U  表示实用新型专利授权公告
Y  表示实用新型专利权部分无效宣告的公告
S  表示外观设计专利授权公告或专利权部分无效宣告的公告

专利文献种类标识代码中数字的含义







（三）专利文献种类标识代码的使用规则

为完整标识一篇专利文献的出版国家，以及在不同程序中的公布或公告，采用中国国家代码CN、专利文献号、专利文献种类标识代码进行联合使用。

国家代码CN  +  专利文献号  +  专利文献种类标识代码  的联合使用
示例：
CN XXXXXXXXX A
CN XXXXXXXXX B
CN XXXXXXXXX C
CN XXXXXXXXX U
CN XXXXXXXXX Y
CN XXXXXXXXX S

示例1：发明专利的公布

示例2：发明专利的授权公告


示例3：实用新型专利的授权公告

示例4：外观设计专利的授权公告


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=56316, encodeId=74a056316f0, content=真是好难懂，受教了，, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56317, encodeId=e3865631e06, content=真是好难懂，受教了，, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56318, encodeId=5a95563187f, content=不错，, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56319, encodeId=1e5b56319c1, content=不错，, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56320, encodeId=4ca9563202f, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56321, encodeId=6620563215e, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    真是好难懂，受教了，

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=56316, encodeId=74a056316f0, content=真是好难懂，受教了，, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56317, encodeId=e3865631e06, content=真是好难懂，受教了，, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56318, encodeId=5a95563187f, content=不错，, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56319, encodeId=1e5b56319c1, content=不错，, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56320, encodeId=4ca9563202f, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56321, encodeId=6620563215e, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    真是好难懂，受教了，

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=56316, encodeId=74a056316f0, content=真是好难懂，受教了，, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56317, encodeId=e3865631e06, content=真是好难懂，受教了，, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56318, encodeId=5a95563187f, content=不错，, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56319, encodeId=1e5b56319c1, content=不错，, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56320, encodeId=4ca9563202f, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56321, encodeId=6620563215e, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    不错，

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=56316, encodeId=74a056316f0, content=真是好难懂，受教了，, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56317, encodeId=e3865631e06, content=真是好难懂，受教了，, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56318, encodeId=5a95563187f, content=不错，, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56319, encodeId=1e5b56319c1, content=不错，, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56320, encodeId=4ca9563202f, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56321, encodeId=6620563215e, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    不错，

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=56316, encodeId=74a056316f0, content=真是好难懂，受教了，, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56317, encodeId=e3865631e06, content=真是好难懂，受教了，, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56318, encodeId=5a95563187f, content=不错，, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56319, encodeId=1e5b56319c1, content=不错，, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56320, encodeId=4ca9563202f, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56321, encodeId=6620563215e, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享～～

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=56316, encodeId=74a056316f0, content=真是好难懂，受教了，, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56317, encodeId=e3865631e06, content=真是好难懂，受教了，, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56318, encodeId=5a95563187f, content=不错，, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56319, encodeId=1e5b56319c1, content=不错，, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56320, encodeId=4ca9563202f, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56321, encodeId=6620563215e, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:41:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享～～

    0

相关资讯

专利侵权判定原则-什么情况下会造成侵权

专利侵权判定原则中国知识产权保护体系采用双轨制，即行政保护和司法保护相结合。被侵权人可以把侵权人的侵权行为诉之于法院，也可以请求行政机关处理。行政程序并不是司法程序的前置程序。中国的司法体系采取二审终审制，大多数知识产权案件的一审法院为中级人民法院，我国于2014年底先后成立了三家知识产权法院（北京、广州、上海），日后的知识产权案件将由知识产权法院和中级法院共同管辖审理。一、如下情形，不视为侵犯专

专利与公益 他们这样寻求平衡

稿件来源：解放日报 印度 私权与公共健康博弈，明智选择后者 2012年，拜耳在印度的败诉，印度本土制药商Natco获得了拜耳药品——多吉美（Nexavar）的专利使用许可。Natco顺利生产其仿制药，并在印度境内进行出售，这使得印度民众以更廉价的方式享用上了这一高效药物，多吉美的价格从每盒28万卢比降至8800卢比，降幅达到97%。 尽管印度专利局的创世之举引起很大的争议，欧美发达国家

医药生物领域--不能申请专利的情形

一、疾病的诊断和治疗方法 是指以有生命的人体或动物体为直接实施对象，进行识别、确定或消除病因或病灶的过程。 出于人道主义的考虑和社会伦理的原因，医生在诊断和治疗过程中应当有选择各种方法和条件的自由； 另外，这类方法直接以有生命的人体或动物体为实施对象，无法在产业上利用，不属于专利法意义上的发明创造，因此，疾病的诊断和治疗方法不能被授予专利权。 例如： 1.外科手术

国内专利资助政策-江浙沪为例

情况说明：专利申请人可以同时享有关于国家及省、市、区的专利资助政策。一、国家级政策国内专利（企业申请）情况说明：费用减缓仅限一个企业申请，两个或两个以上的单位共同申请，费用不予减缓。发明专利：申请费、实质审查费、授权前三年年费，费用减缓70%；实用新型专利：申请费、授权前三年年费，费用减缓70%；外观设计专利：申请费、授权前三年年费，费用减缓70%。国内专利（个人申请）情况说明：两个或两个以上

案例介绍—医药生物领域的授权专利

1、用于实施疾病诊断和治疗方法的仪器或装置例如:诊断和治疗用的仪器设备或手术器械。案例：一种重叠覆盖椭球体的消融灶产生系统及方法（授权公告号 CN 100484491 C）一种治疗肛瘘的压力控制单向挂线器（授权公告号 CN 100581488 C）医用封堵器抗压能力测试装置（授权公告号 CN 102435501 B）一种多功能医用洗头装置(授权公告号 CN 203263699 U)一种手术撑开

科研工作者需谨记专利的重要性

专利制度是国际上通行的一种国家利用法律和经济手段保护发明创造者的合法权益，鼓励发明创造，推动科学技术进步的一项重要法律制度。知识产权日益成为国家发展的战略性资源和核心要素，在激励创新、推动经济发展和社会进步中的支撑作用日益凸显。1、专利的价值专利是一种无形财产权，受到法律的保护，具有价值和使用价值，有些重大专利的价值要远远高于房屋、汽车等有形财产。专利即是盾，保护自己的技术和产品，也是矛，可以